Ocugen (OCGN) Accumulated Expenses (2014 - 2026)
Ocugen's (OCGN) quarterly Accumulated Expenses came in at $11.6 million in Q1 2026, down 10.17% YoY from $12.9 million in Q1 2025, and down 21.18% on a QoQ basis from $14.7 million in Q4 2025.
Ocugen (OCGN) Accumulated Expenses (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Accumulated Expenses data on file, last reported at $11.6 million in Q1 2026.
- Quarterly Accumulated Expenses fell 10.17% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (down 10.17% YoY) and the FY2025 annual result came in at $14.7 million, down 4.95% from the prior year.
- Accumulated Expenses retreated to $11.6 million in Q1 2026, from $14.7 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $20.0 million in Q4 2022 to a low of $9.2 million in Q1 2022.
- A 5-year average of $14.3 million and a median of $13.3 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses surged 361.76% — and 2023, when it plunged 33.19%.
- Tracing OCGN's Accumulated Expenses over 5 years: stood at $20.0 million in 2022, then sank by 33.19% to $13.3 million in 2023, then gained by 16.17% to $15.5 million in 2024, then declined by 4.95% to $14.7 million in 2025, then decreased by 21.18% to $11.6 million in 2026.
- The last three Accumulated Expenses figures came in at $11.6 million (Q1 2026), $14.7 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.01 Mn |
| Mar 31, 2026 | 11.61 Mn |
| Dec 31, 2025 | 14.73 Mn |
| Sep 30, 2025 | 14.93 Mn |
| Jun 30, 2025 | 12.90 Mn |
| Mar 31, 2025 | 12.93 Mn |
| Dec 31, 2024 | 15.50 Mn |
| Sep 30, 2024 | 12.48 Mn |
| Jun 30, 2024 | 12.81 Mn |
| Mar 31, 2024 | 12.43 Mn |
| Dec 31, 2023 | 13.34 Mn |
| Sep 30, 2023 | 14.99 Mn |
| Jun 30, 2023 | 18.83 Mn |
| Mar 31, 2023 | 16.72 Mn |
| Dec 31, 2022 | 19.97 Mn |
| Sep 30, 2022 | 17.62 Mn |
| Jun 30, 2022 | 11.73 Mn |
| Mar 31, 2022 | 9.15 Mn |
| Dec 31, 2021 | 4.33 Mn |
| Sep 30, 2021 | 3.96 Mn |